ENTO - חוב כולל להון Entero Therapeutics

The price evolution of Entero Therapeutics, Inc. (ENTO) demonstrates a total debt-to-equity ratio of 0.01. The business is implementing automated data analysis software for celiac disease and testing robotic stations. Market protection is ensured by unique patents and strict FDA control. The development of new GI drugs relies on close cooperation with specialized medical centers and joint research.

Developing innovative drugs for the treatment of celiac disease requires significant investment, making the analysis of Entero Therapeutics, Inc. (ENTO) financing structure critically important. This financial risk metric (debt-to-equity) reflects the proportion of borrowed funds relative to equity; the low values on this chart confirm the business's resilience to credit risks and the issuer's high investment attractiveness.